Two Sigma Advisers
NBRV

Two Sigma Advisers’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Two Sigma Advisers’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-94
Closed -$31K – 2625
2019
Q4 		$31K Buy
94
+5
+6% +$2.29K ﹤0.01% 2309
2019
Q3 		$45K Buy
89
+36
+68% +$20.3K ﹤0.01% 2158
2019
Q2 		$32K Sell
53
-39
-42% -$23.9K ﹤0.01% 2274
2019
Q1 		$56K Sell
92
-9
-9% -$4.91K ﹤0.01% 2228
2018
Q4 		$37K Buy
+101
New +$54.3K ﹤0.01% 2294

Other funds holding NBRV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FNC
First National Corp Rockland, Massachusetts $527M AUM 12.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VFA
Values First Advisors Gray, Tennessee $192M AUM 24.96% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Two Sigma Advisers's NBRV Position: Q1 2020 in Review

Two Sigma Advisers sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q1 2020, closing a stake of 94 shares — an estimated $31K sold.

Two Sigma Advisers first reported a position in NBRV in Q4 2018 and held it in 5 quarters. The position peaked at $56K in Q1 2019. 50 funds tracked by Wall St. Rank hold NBRV as of Q1 2020.

  • Two Sigma Advisers reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q1 2020 after selling out during the quarter.
  • Two Sigma Advisers sold 94 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q1 2020, an estimated $31K.
  • Two Sigma Advisers first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2018 and held it in 5 quarters.
  • Two Sigma Advisers's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $56K in Q1 2019.
  • 50 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q1 2020.

Based on Two Sigma Advisers's 13F filing for Q1 2020, filed 15 May 2020.